Prescribing Divalproex/Valproate (Depakote)

Why Valproate Still Matters

Valproate is the workhorse anticonvulsant mood stabilizer, fast, flexible, and genuinely useful for the presentations where lithium struggles. Where lithium owns the classic euphoric-mania-then-euthymia patient, valproate earns its keep in the messier bipolar spectrum: mixed features, rapid cycling, irritable/dysphoric mania, and bipolar with comorbid substance use. You can load it quickly, you can dose it flexibly, it doesn't require you to worry about the kidney the way lithium does, and it works for a substantial fraction of patients who never fit the Kraepelinian mold.

It is also one of the few mood stabilizers with a genuine dual indication, FDA-approved for both bipolar mania and migraine prophylaxis, which makes it a natural pick for the bipolar patient who also gets migraines.

But valproate demands respect for a completely different set of hazards than lithium. Lithium's dangers are renal and toxicologic; valproate's are hematologic (thrombocytopenia), hepatic (rare fatal hepatotoxicity), pancreatic (rare pancreatitis), metabolic (weight gain), endocrine-reproductive (PCOS), and, above all, reproductive-teratogenic. Valproate is the single most teratogenic drug in the mood-stabilizer cabinet, and that fact should shape every prescribing decision you make for a woman of reproductive age.

This guide is about using valproate well: knowing exactly who it's for, loading and monitoring it correctly, catching its distinctive adverse effects early, and, critically, keeping it away from patients for whom its reproductive and cognitive-teratogenic risks make it the wrong choice. Used with those guardrails, valproate is a reliable, effective, and mostly well-tolerated tool.

A note on expectations, set honestly up front: in the real world, valproate's maintenance evidence is softer than its reputation. The large, unenriched STEP-BD program did not show valproate (or lithium) clearly superior to placebo for long-term bipolar maintenance in unselected patients. Valproate's strongest, most defensible role is acute and mixed mania and stabilization of the unstable, irritable, rapid-cycling patient, not necessarily lifelong monotherapy prophylaxis in every bipolar patient.

Part 1: Indications: Who Is Valproate For?

FDA-Approved Uses

• Acute mania in bipolar disorder (including mixed episodes)
• Migraine prophylaxis (one of the few mood stabilizers with a dual psychiatric/neurologic indication)
• Epilepsy (absence, partial, and generalized seizures)

Note the gap: valproate is not robustly established as a maintenance monotherapy the way lithium and lamotrigine are. It is used for maintenance in practice, but the maintenance evidence is weaker than the acute-mania evidence.

The Evidence-Based Clinical Uses

Acute and mixed mania: valproate's home turf. Among anticonvulsants, valproate and carbamazepine are the two that have genuinely "passed" controlled trials in mania; lamotrigine, gabapentin, and topiramate have failed. Valproate is fast, can be loaded, and works. It is particularly favored for the presentations where lithium is weakest:

• Mixed episodes / mixed features (dysphoric mania, depression-plus-activation)
• Rapid cycling
• Irritable or dysphoric mania rather than classic euphoric mania
• Bipolar with comorbid alcohol or substance use disorder

Maintenance bipolar: with honest expectations. Valproate is used for maintenance, but temper your expectations. In the large, real-world, unenriched STEP-BD program, neither valproate nor lithium was clearly superior to placebo for long-term maintenance in unselected patients, and recovery rates hovered around 50–60% with relapse near 50%. Set realistic goals with patients and consider combination therapy rather than assuming monotherapy prophylaxis will hold.

Bipolar depression: adjunctive, modest. Valproate is not a strong acute antidepressant. As an adjunct to another mood stabilizer, one line of data shows response rates around 57% for the combination vs 42% for placebo in bipolar depression, useful, but this is add-on territory, not monotherapy for the depressed pole.

Combination therapy. Valproate is frequently added to lithium for bipolar I (a classic, well-tolerated pairing) and used to augment antipsychotics in breakthrough mania. Adding valproate to lithium is a mainstream move for the treatment-resistant bipolar I patient.

Aggression, impulsivity, and agitation (off-label). This is a large, real-world use even outside bipolar disorder:

• Borderline personality disorder: meta-analytic data show mood stabilizers including valproate have large effects on impulse control, anger, and anxiety, with moderate effects on depression and global functioning.
• Aggression in ADHD: valproate produced improvements similar to risperidone with fewer side effects.
• Agitation/aggression in schizophrenia (inpatient), TBI, developmental disability, and PTSD, commonly used, though the RCT evidence is thin and short-term benefit in some settings is "contestable."

Migraine with bipolar comorbidity. When a bipolar patient also has migraines, valproate is one option that treats both. (If there's no bipolar indication, topiramate is often preferred for migraine on tolerability grounds.)

Where Valproate Is a Poor Fit

• Bipolar II. Strong mood stabilizers like valproate can "flatten" bipolar II patients and leave them feeling depressed, especially at higher doses. Lamotrigine is the better-tolerated, depression-focused first choice here; if valproate is used in bipolar II, favor combination over monotherapy and keep doses modest.
• Behavioral/psychological symptoms of dementia (BPSD). Well-designed studies show no benefit over placebo. Don't use it here.
• Tardive dyskinesia. Limited efficacy; not a reliable treatment.
• Any woman who may become pregnant where a reasonable alternative exists (see Special Populations).

Part 2: Before You Start: Workup and Candidacy

Baseline Labs

What you do NOT need to check routinely: baseline amylase and lipase. The baseline is almost never abnormal, pancreatitis is rare and comes on quickly rather than gradually, and periodic screening won't reliably catch it early. Check amylase/lipase only if symptoms of pancreatitis appear (severe abdominal pain, nausea, vomiting).

Screen These Patients OUT Before Prescribing

• Active hepatic disease or significant hepatic dysfunction (hepatotoxicity risk)
• Known or suspected mitochondrial disorders (e.g., POLG-related disorders): risk of fatal hepatotoxicity; contraindicated
• Urea cycle disorders: valproate can precipitate fatal hyperammonemic encephalopathy
• Pregnancy (especially first trimester), or a woman planning pregnancy where an alternative exists
• Children under ~2 years, especially on anticonvulsant polypharmacy (highest hepatotoxicity risk)
• Known hypersensitivity to valproate
• Bleeding disorders / significant thrombocytopenia (relative)

Part 3: How to Start and Dose

Formulations: Know the Differences

• Divalproex sodium (Depakote): enteric-coated, delayed-release; a stable compound of valproic acid and sodium valproate. Much gentler on the GI tract than valproic acid; this is your default psychiatric formulation.
• Divalproex sodium ER (Depakote ER): once-daily dosing convenience; often better tolerated. May not be covered by insurance, but is available cheaply through some programs.
• Valproic acid (Depakene): available as liquid and capsules; more GI-irritating. Its niche is settings where you must verify ingestion (e.g., correctional facilities or patients who "cheek" pills) because liquid is hard to fake. The GI irritation is an accepted tradeoff for guaranteed adherence.
• Sprinkles: useful for patients who can't swallow tablets; may reduce GI upset.

Starting Dose and Titration

• Typical start: 250–500 mg BID (divalproex), or dose by weight.
• Weight-based target: roughly 15–20 mg/kg/day, often landing around 1,000–1,500 mg/day in studies.
• Loading (acute mania): valproate can be loaded when you need speed, one advantage over lithium and lamotrigine. Loading strategies (e.g., ~20–30 mg/kg/day) get therapeutic levels quickly in the acutely manic inpatient. Titrate more gently in the outpatient setting to spare GI tolerability.
• Because the half-life is short (~8–17 hours), immediate-release/delayed-release products are typically dosed BID–TID; ER products allow once-daily dosing.

Target Serum Levels

There is no crisp FDA-endorsed psychiatric target; 50–100 mcg/mL is the working consensus for mania.

Steady state arrives in ~2–3 days. Check a level about 5 half-lives (a few days) after any dose change, much faster than lithium's 5-day wait.

The Free-Level Trick (Important and Underused)

Valproate is highly protein-bound (~90–95%), and only the free (unbound) fraction is pharmacologically active. In most patients the total level tracks the free level well enough. But protein binding is saturable and can be disrupted:

• In patients on aspirin or other highly protein-bound drugs, in hypoalbuminemia, in the elderly, or at high total levels, the free fraction can be dangerously high despite a normal-looking total level.
• In those situations, order a free valproate level (target ~5–10 mcg/mL) rather than trusting the total.

Part 4: Monitoring: The Schedule

Core labs

What to watch clinically (not by routine lab)

• Hepatotoxicity: highest risk in the first 6 months. Educate the patient to report abdominal pain, nausea/vomiting, jaundice, malaise, unusual lethargy. Check LFTs if symptoms arise.
• Pancreatitis: don't screen amylase/lipase routinely; check only if abdominal pain develops.
• Hyperammonemia: don't screen routinely; check an ammonia level if new confusion, lethargy, or encephalopathy appears, even with a normal valproate level.
• PCOS (women 18–44): monitor menstrual regularity, hirsutism, acne; check testosterone if symptoms emerge.
• Weight: track at every visit; it's one of the more common reasons patients quit.

The specific thresholds to act on

• Platelets <150,000/μL: thrombocytopenia. Mild and asymptomatic → monitor and often reduce dose (especially if level is high). Significant or symptomatic (bruising, bleeding, petechiae) → reduce dose or discontinue.
• Rising transaminases: mild, asymptomatic elevations are common and often tolerable; symptomatic elevation, jaundice, or rapidly rising LFTs → stop and evaluate for hepatotoxicity.
• New encephalopathy with normal VPA level: check ammonia.
• PCOS symptoms: counsel, check testosterone, and consider switching agents.

Part 5: Side Effects and How to Manage Them

The governing principle mirrors lithium's: most valproate side effects are dose- and level-dependent, most are manageable, and side effects, not lack of efficacy, are the usual reason patients quit. But the specific menu is entirely different from lithium's.

Gastrointestinal (nausea, dyspepsia)

Common early, especially with valproic acid.

Management:

• Use enteric-coated divalproex (Depakote), not valproic acid (Depakene). This is the single biggest GI lever.
• Consider ER or the sprinkles formulation.
• Take with food; titrate more slowly.

Hematologic: Thrombocytopenia

Not rare. Roughly 17.7% (about 1 in 6) of epilepsy patients had at least one episode of thrombocytopenia (platelets <150,000/μL) in one 265-patient series.

• More common in women.
• Level-dependent: risk climbs above ~100 mcg/mL in women, ~130 mcg/mL in men.
• Valproate can also cause platelet dysfunction (impaired function even with an adequate count), relevant before surgery.

Management:

• Baseline platelets → 2-week recheck → periodic.
• Counsel on bruising/bleeding.
• Mild/asymptomatic: monitor, often lower the dose (which lowers the level).
• Significant/symptomatic: reduce dose or discontinue; consider hematology if severe.

Metabolic: Weight Gain

Common and a major adherence problem.

• Occurs in ~20–25% of patients; typically 3–10 kg over 3–12 months. Some long-term epilepsy data are more dramatic (mean gain of ~21 kg in a subset of women over years).
• In women, weight gain and PCOS can feed each other.

Management:

• Diet and activity counseling from the start; set expectations.
• If the patient is also on a metabolically costly antipsychotic, trim the antipsychotic first: it's usually the bigger culprit.
• Consider metformin as an adjunct in patients gaining significant weight.

Endocrine/Reproductive: PCOS (Women 18–44)

A confirmed, distinctive valproate risk that clinicians routinely underappreciate. In STEP-BD, 10.5% of women on valproate (9 of 86) developed PCOS symptoms vs 1.4% on non-valproate stabilizers/lithium (2 of 144).

• Features: menstrual irregularity, hirsutism, acne, male-pattern hair loss, elevated testosterone.

Management:

• Warn women of reproductive age before starting. This is a consent-level disclosure.
• Monitor menstrual regularity, hirsutism, acne; check testosterone if symptoms develop.
• If PCOS emerges, consider switching agents and involve gynecology.

Dermatologic/Cosmetic: Hair Loss (Alopecia)

Clinically significant and distressing, though poorly studied. Thought to relate to impaired absorption of trace micronutrients.

Management (a genuinely useful practical protocol):

• Supplement zinc (~22 mg, chelated), selenium (~200 mcg), and biotin (~10 mg) daily.
• Take supplements at a different time of day than the valproate: the drug interferes with their absorption.
• Reassure: follicles aren't destroyed, so hair regrows if the supplements work or the drug is stopped.
• No single multivitamin carries these at adequate doses, so they must be taken separately.

Neurological: Tremor and Sedation

• Tremor: often dose-related; lower the dose, and propranolol can be used as with other action tremors.
• Sedation/drowsiness: variable; often improves with time or with dose/timing adjustment.

Cognitive/CNS

• Valproate has GABAergic activity and can increase the risk of complex sleep behaviors when combined with z-hypnotics (zolpidem and cousins), a pharmacodynamic interaction worth remembering.

Sexual

• Sexual side effects are possible but tend to be less than with enzyme-inducing anticonvulsants (carbamazepine, oxcarbazepine), which raise SHBG and lower free testosterone. Valproate, being non-inducing, is comparatively easier on this axis.

Cardiac (a reassuring note)

• Valproate is relatively safe for cardiac conduction: it does not block sodium channels the way carbamazepine, oxcarbazepine, topiramate, and lamotrigine do. Those agents are avoided when the QRS is >110 ms; valproate (with gabapentin and pregabalin) is a safer choice in patients with conduction concerns.

Part 6: Toxicity and the Boxed Warnings

Valproate carries four FDA boxed warnings. Know them cold.

Overdose and acute toxicity

• Signs of high levels: somnolence, ataxia, tremor, confusion, and at the extreme coma.
• Hyperammonemia can occur even at therapeutic levels and cause encephalopathy; check ammonia in any valproate patient with unexplained new confusion or lethargy.
• Valproate has a narrow therapeutic index; modest level changes can matter. Manage overdose supportively; severe cases may involve the ED, and L-carnitine is used for valproate-induced hyperammonemia and serious toxicity.

Part 7: Drug Interactions

Valproate is metabolized hepatically (largely by mitochondrial β-oxidation and glucuronidation), with limited CYP450 involvement compared with carbamazepine. Its interactions cluster in three buckets: protein-binding displacement, the lamotrigine interaction, and level-based additive effects.

The lamotrigine interaction: the one you must not miss

Valproate roughly DOUBLES lamotrigine levels by inhibiting lamotrigine's glucuronidation (UGT1A4). This is a major, clinically dangerous interaction because it directly raises the risk of Stevens-Johnson syndrome on lamotrigine.

• When adding lamotrigine to a patient on valproate, use the reduced lamotrigine titration schedule (roughly half the usual doses) and titrate especially slowly.
• This is one of the most tested, most consequential interactions in bipolar pharmacology. Get it wrong and you can cause a life-threatening rash.

Protein-binding displacement

• Aspirin (and other highly protein-bound drugs) displace valproate from serum proteins, raising the free (active) fraction, potential toxicity despite a normal total level.
• Management: in patients on aspirin or with hypoalbuminemia, order a free valproate level rather than trusting the total.

Valproate as an inhibitor (levels of other drugs rise)

• Valproate can raise the levels of some antipsychotics and other co-prescribed psychotropics. Watch for additive sedation or increased side effects when combining.
• Combined with z-hypnotics, its GABAergic activity increases the risk of complex sleep behaviors.

Drugs that lower valproate levels

• Potent CYP3A4 inducers (carbamazepine, rifampin, phenytoin, phenobarbital) reduce valproate levels: watch for loss of efficacy when they're co-prescribed, and for level swings when they're started or stopped.

Folic acid / l-methylfolate nuance

• Folic acid may augment valproate (and antidepressants), but in patients also on lamotrigine, folic acid can nullify lamotrigine's benefit in a genetically defined subset (COMT-related). l-Methylfolate (the CNS-active form) does not appear to carry this interaction and is the safer supplement in a lamotrigine-treated patient.

Narrow therapeutic index

• Like lithium, tricyclics, and carbamazepine, valproate has a narrow therapeutic index: modest level differences can have outsized effects. Respect the level.

Part 8: Special Populations

Pregnancy: The Defining Risk

Valproate is the most teratogenic mood stabilizer, and this fact should govern agent selection for anyone who could become pregnant.

• Neural tube defects: ~5% (vs a 0.05–0.1% baseline), making valproate roughly 50–100× more teratogenic than lithium.
• Spina bifida: 12–16× higher than baseline.
• Other anomalies (2–7× risk): atrial septal defects, hypospadias, cleft palate, polydactyly, craniosynostosis.
• Neurodevelopmental toxicity: children exposed, even after the first trimester, show lower IQ and poorer cognitive outcomes than children exposed to other antiepileptic monotherapies or none. This is not just a first-trimester structural problem; it's a whole-pregnancy cognitive one.

Prevention efforts have limited efficacy:

• High-dose folic acid (4–5 mg/day): did not reduce the birth-defect rate in one study (though it reduced miscarriage risk). Don't count on folate to make valproate safe in pregnancy.
• Vitamin K (20 mg/day) in the last month: recommended to reduce neonatal bleeding risk.

The clinical verdict:

• Avoid valproate in pregnancy, especially the first trimester.
• For a bipolar woman of reproductive age who needs a mood stabilizer, prefer lamotrigine or an atypical antipsychotic. Even lithium, despite its heavier monitoring burden, is substantially safer teratogenically than valproate.
• If a patient of reproductive potential is on valproate, ensure reliable contraception and a documented risk conversation, and revisit the agent choice at every opportunity.

Weigh this against the real danger of untreated illness: in one cohort of 89 pregnant bipolar women, 70% stopped mood stabilizers and were more than twice as likely to relapse (85% vs 37%), and abrupt discontinuation caused far faster relapse (~2 weeks) than gradual (~22 weeks). The lesson is not "keep valproate"; it's switch to a safer agent well before conception rather than stopping cold.

Breastfeeding

• Considered relatively safe: valproate levels in breast milk are low.
• Residual concerns: theoretical infant hepatotoxicity and a questionable reported case of infant thrombocytopenia.
• If the mother breastfeeds, watch the infant for unusual bruising or bleeding, and consider checking infant valproate level, platelets, and LFTs if there's any concern.

Elderly

• No routine dose adjustment for age alone, but the elderly are more vulnerable to side effects.
• Watch thrombocytopenia and hyponatremia more vigilantly.
• Free-level considerations matter more (lower albumin, polypharmacy): check free levels when toxicity is suspected but the total looks normal.

Renal Impairment

• Rare valproate-associated acute kidney injury is reported; a Stockholm cohort found roughly 3.2% AKI over 10 years (comparable to lithium; both low).
• Moderate-to-severe renal (or hepatic) impairment: reduce to roughly 50% of the usual dose and monitor.
• Baseline creatinine/eGFR is prudent; avoid in severe renal disease.

Hepatic Impairment

• Contraindicated in active hepatic disease.
• Rare but potentially fatal hepatotoxicity, concentrated in the first 6 months and in high-risk groups; monitor LFTs closely, particularly on polypharmacy.
• Reduce dose in moderate-to-severe hepatic impairment.

Pediatric

• Epilepsy indications are established; bipolar use is off-label.
• Highest hepatotoxicity risk is in children under 2 on polypharmacy, a group to avoid.
• Any female pediatric patient reaching reproductive age inherits the full teratogenic risk; factor this into long-term planning.

Part 9: Discontinuation

Valproate lacks lithium's dramatic, well-quantified rebound signature, and there is no rigid FDA-mandated taper. But do not stop it abruptly in a mood-disorder patient: the general mood-stabilizer principle holds that abrupt discontinuation drives faster relapse than gradual withdrawal.

• Taper gradually rather than stopping cold. A reasonable pace parallels other anticonvulsant mood stabilizers, on the order of ~5–10% per month for a long-term patient, adjusted to clinical stability.
• The pregnancy data make the point vividly: abrupt cessation triggered relapse in ~2 weeks vs ~22 weeks for gradual cessation. If you're stopping for pregnancy planning, switch or taper deliberately and ahead of time, not reactively.
• A special caution when co-prescribed with lamotrigine: because valproate doubles lamotrigine levels, stopping valproate will roughly halve the lamotrigine level. Anticipate loss of lamotrigine efficacy and adjust the lamotrigine dose upward as you withdraw the valproate. (And if lamotrigine has been off for more than ~5 days for any reason, it must be re-titrated from the start to avoid rash.)
• The message to patients: "It's far easier to prevent a relapse than to treat an episode, so we taper slowly, and we never stop on our own."

Part 10: Valproate vs the Alternatives

• vs Lithium. Similar short-term antimanic efficacy; lithium is superior as monotherapy in classic bipolar I (and uniquely reduces suicide), while valproate is preferred for mixed features, rapid cycling, and comorbid substance use. Both carry low, comparable renal-injury risk (~3.5% CKD over 10 years in the Stockholm cohort; AKI slightly favors lithium). Lithium needs more intensive monitoring (levels, renal, thyroid); valproate avoids the renal/thyroid worry but adds hepatic, hematologic, and metabolic ones. Lithium is dramatically safer in pregnancy (0.05–0.1% Ebstein's vs 5% NTD). Lithium + valproate is a mainstream, effective combination for resistant bipolar I.
• vs Lamotrigine. Lamotrigine is the better maintenance and depression-prevention agent and the far better tolerated one (no weight gain, no PCOS), and it is much safer in pregnancy (~2.2% defect rate, within baseline). Valproate is better for acute/mixed mania, which lamotrigine does not treat. Remember the interaction: valproate doubles lamotrigine, so combining them demands a reduced lamotrigine titration.
• vs Carbamazepine. Both "pass" in mania. Carbamazepine is a potent CYP3A4 inducer with a heavy interaction burden and hematologic risks (agranulocytosis, aplastic anemia); valproate's interaction profile is lighter and it doesn't cause those hematologic catastrophes. Both are teratogenic (NTDs).
• vs Atypical antipsychotics. Antipsychotics are safer in pregnancy and are preferred first-line for reproductive-age women; they also act fast in acute mania. Valproate is favored for non-psychotic mixed/rapid-cycling presentations and for agitation across diagnoses.

Where valproate wins: speed and loadability in acute/mixed mania; the messy, non-classic, rapid-cycling, substance-using bipolar patient; the bipolar-plus-migraine patient; agitation and impulsivity across diagnoses; and a comparatively clean cardiac-conduction and drug-interaction profile.

Where valproate loses: any woman who might become pregnant (teratogenicity + IQ effects); bipolar II (flattening); pure maintenance monotherapy (soft evidence); and patients where weight gain or PCOS would be especially costly.

Mechanism: The Short Version

Valproate's mood mechanism is not fully understood, but the leading actions are:

• Enhanced GABA neurotransmission (increased GABA synthesis, reduced catabolism): the classic account.
• Blockade of voltage-gated sodium channels (shared with other anticonvulsants).
• Histone deacetylase (HDAC) inhibition: an emerging epigenetic mechanism that may contribute to mood stabilization and neuroprotection.

Pharmacokinetics that shape prescribing:

• Half-life ~8–17 hours → BID–TID dosing for standard forms, once-daily for ER.
• Protein binding ~90–95%, saturable → the free-fraction traps described above.
• Hepatic metabolism (mitochondrial β-oxidation, glucuronidation) → the hepatotoxicity and hyperammonemia risks, and the lamotrigine (UGT) interaction.
• Steady state ~2–3 days → fast level feedback, and the ability to load in acute mania.

Historically, valproic acid was synthesized in 1882 as a simple fatty acid and used for decades merely as an inert organic solvent, until, in 1960s Grenoble, compounds dissolved in it were noticed to have anticonvulsant effects that turned out to be the solvent itself. Abbott later created divalproex (Depakote) as a better-tolerated formulation.

Bedside Cheat Sheet